← Oncology Approval Tracker

FDA DECISION ·

Talzenna + enzalutamide

talazoparib with enzalutamide · Pfizer

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer and homologous recombination repair (HRR) gene mutations identified by an FDA-authorized test.

LAMPGEN ANALYSIS

Why it matters

This PARP inhibitor combination moves into an earlier metastatic setting for patients with qualifying HRR mutations. Distinguish this population from the existing castration-resistant indication.

What research teams should watch

Build a review trail for the HRR result, prior androgen-pathway treatment and the timing of testing. Use the trial report to distinguish radiographic progression from survival outcomes.

PRIMARY RECORDS

Sources